Teva Tells Justices $235M Loss 'Erodes' Patent Law
Teva Pharmaceuticals is warning the U.S. Supreme Court that an appeals court's revival of a Delaware federal jury's $235 million award for GlaxoSmithKline in its patent infringement suit against the Israeli drugmaker...To view the full article, register now.
Already a subscriber? Click here to view full article